@article{discovery10055834,
            note = {{\copyright} The Author(s) (2018). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com},
           pages = {2721--2739},
           title = {The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target},
          volume = {141},
         journal = {Brain},
           month = {September},
            year = {2018},
          number = {9},
             url = {https://doi.org/10.1093/brain/awy215},
            issn = {1460-2156},
        abstract = {Our hypothesis is that changes in gene and protein expression are crucial to the development of late-onset Alzheimer's disease. Previously we examined how DNA alleles control downstream expression of RNA transcripts and how those relationships are changed in late-onset Alzheimer's disease. We have now examined how proteins are incorporated into networks in two separate series and evaluated our outputs in two different cell lines. Our pipeline included the following steps: (i) predicting expression quantitative trait loci; (ii) determining differential expression; (iii) analysing networks of transcript and peptide relationships; and (iv) validating effects in two separate cell lines. We performed all our analysis in two separate brain series to validate effects. Our two series included 345 samples in the first set (177 controls, 168 cases; age range 65-105; 58\% female; KRONOSII cohort) and 409 samples in the replicate set (153 controls, 141 cases, 115 mild cognitive impairment; age range 66-107; 63\% female; RUSH cohort). Our top target is heat shock protein family A member 2 (HSPA2), which was identified as a key driver in our two datasets. HSPA2 was validated in two cell lines, with overexpression driving further elevation of amyloid-{\ensuremath{\beta}}40 and amyloid-{\ensuremath{\beta}}42 levels in APP mutant cells, as well as significant elevation of microtubule associated protein tau and phosphorylated-tau in a modified neuroglioma line. This work further demonstrates that studying changes in gene and protein expression is crucial to understanding late onset disease and further nominates HSPA2 as a specific key regulator of late-onset Alzheimer's disease processes.},
        keywords = {genetic network; Alzheimer's disease; dementia; transcriptomics; proteomics},
          author = {Petyuk, VA and Chang, R and Ramirez-Restrepo, M and Beckmann, ND and Henrion, MYR and Piehowski, PD and Zhu, K and Wang, S and Clarke, J and Huentelman, MJ and Xie, F and Andreev, V and Engel, A and Guettoche, T and Navarro, L and De Jager, P and Schneider, JA and Morris, CM and McKeith, IG and Perry, RH and Lovestone, S and Woltjer, RL and Beach, TG and Sue, LI and Serrano, GE and Lieberman, AP and Albin, RL and Ferrer, I and Mash, DC and Hulette, CM and Ervin, JF and Reiman, EM and Hardy, JA and Bennett, DA and Schadt, E and Smith, RD and Myers, AJ}
}